Media headlines about Biomerica (NASDAQ:BMRA) have been trending somewhat negative on Saturday, according to Accern Sentiment Analysis. The research firm rates the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Biomerica earned a coverage optimism score of -0.05 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 51.0290145693132 out of 100, meaning that recent media coverage is somewhat likely to have an impact on the stock’s share price in the next several days.

NASDAQ BMRA traded up $0.02 on Friday, reaching $3.59. The company had a trading volume of 4,053 shares, compared to its average volume of 8,131. The company has a market capitalization of $31.92 million, a price-to-earnings ratio of -21.09 and a beta of -0.66. Biomerica has a fifty-two week low of $2.68 and a fifty-two week high of $9.32.

Biomerica (NASDAQ:BMRA) last posted its quarterly earnings data on Thursday, August 30th. The company reported ($0.08) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.02). The company had revenue of $1.13 million during the quarter, compared to analyst estimates of $1.53 million. Biomerica had a negative net margin of 19.46% and a negative return on equity of 27.29%. sell-side analysts anticipate that Biomerica will post -0.33 earnings per share for the current year.

Biomerica Company Profile

Biomerica, Inc, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; and to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations.

Recommended Story: Penny Stocks, Risk and Reward Factors

Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with's FREE daily email newsletter.